U.S. Federal Trade Commission (FTC) · United States

FTC CBD Advertising - Health Claim Prohibitions

FTC law bars unsubstantiated disease, treatment and drug-replacement claims for CBD and cannabinoid products; a 'not evaluated by FDA' disclaimer does not fix them.

FTC Act 5, 12 (15 U.S.C. 45, 52); FTC Health Products Compliance Guidance (2022)

What is FTC CBD Advertising - Health Claim Prohibitions?

FTC law bars unsubstantiated disease, treatment and drug-replacement claims for CBD and cannabinoid products; a 'not evaluated by FDA' disclaimer does not fix them. Apply to US CBD, hemp and cannabinoid ads and posts that claim effects on pain, anxiety, sleep, inflammation or specific diseases.

US Federal

Read official source

Last reviewed: 2026-11-05

General information, not legal advice.

Who does this rule apply to?

general_audience, general_adults_18plus, adults_21plus, customers · Cannabis, Cannabis (CBD), CBD · advertising marketing

Where does this rule apply?

United States

Which marketing channels are covered?

all_channels

When does this rule take effect?

2026-05-10

What does this rule require?

FTC law bars unsubstantiated disease, treatment and drug-replacement claims for CBD and cannabinoid products; a 'not evaluated by FDA' disclaimer does not fix them.

How can marketing teams comply?

Apply to US CBD, hemp and cannabinoid ads and posts that claim effects on pain, anxiety, sleep, inflammation or specific diseases.

Where can I read the official source?

Read official source

Key facts

Regulatory authority
U.S. Federal Trade Commission (FTC)
Jurisdiction
United States
Official citation
FTC Act 5, 12 (15 U.S.C. 45, 52); FTC Health Products Compliance Guidance (2022)
Published
2026-11-16
Effective date
2026-05-10
Channel
all_channels
Products
Cannabis, Cannabis (CBD), CBD
Audiences
general_audience, general_adults_18plus, adults_21plus, customers

Frequently asked questions

What is FTC CBD Advertising - Health Claim Prohibitions?

FTC law bars unsubstantiated disease, treatment and drug-replacement claims for CBD and cannabinoid products; a 'not evaluated by FDA' disclaimer does not fix them.

Who does this rule apply to?

general_audience, general_adults_18plus, adults_21plus, customers · Cannabis, Cannabis (CBD), CBD · advertising marketing

Where does this rule apply?

United States

Which marketing channels are covered?

all_channels

When does this rule take effect?

2026-05-10

Request a free compliance scan of your homepage and book a time with Warrant.

Get a free homepage compliance scan